Sapience Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Team
    • Directors
    • Advisors
  • Our Approach
    • Overview
    • Therapeutic Approach
    • Discovery Platform
  • Pipeline
    • Overview
    • ST101
    • β-Catenin Antagonist
    • cJun Antagonist
    • cMyc Antagonist
    • FoxP3 Antagonist
    • Expanded Access
  • Partnering
  • Careers
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Contact

Press Releases

News & Events

News & Events

  • Press Releases
  • Events
  • Publications
  • Presentations
  • Email Alerts
Feb 03, 2022 4:05pm EST

Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference

Jan 06, 2022 8:00am EST

Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101

Dec 15, 2021 8:16am EST

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma

Dec 09, 2021 8:00am EST

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium

Dec 06, 2021 8:00am EST

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

Dec 01, 2021 4:05pm EST

Sapience Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Conference

Nov 10, 2021 4:05pm EST

Sapience Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

Oct 29, 2021 11:00am EDT

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at 28th Prostate Cancer Foundation Annual Scientific Retreat and 18th International Congress of the Society for Melanoma Research

Oct 12, 2021 8:00am EDT

Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program

Oct 04, 2021 8:00am EDT

Sapience Therapeutics Announces Oral Presentation on ST101 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next
RSS
© 2022 Sapience Therapeutics, Inc. All Rights Reserved.
linkedin
Privacy Policy Disclaimer Sitemap